Jupiter Neurosciences, Inc. (JUNS)
| Market Cap | 145.66M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.34M |
| Shares Out | 33.10M |
| EPS (ttm) | -0.05 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 115,214 |
| Open | 4.160 |
| Previous Close | 4.270 |
| Day's Range | 4.160 - 4.750 |
| 52-Week Range | 3.860 - 19.510 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 11, 2025 |
About JUNS
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products primarily for the treatment of neuroinflammation. It is developing JNS101, which is in Phase II trial for the treatment of Friedreich's Ataxia, a rare inherited disease that causes damage to the nervous system, as well as mobility dysfunctions; and JNS108 that is in Phase II trial for treating mild cognitive impairment/early Alzheimer’s disease. The company is also developing JNS102, which is in Phase II trial fo... [Read more]
Financial Performance
Financial StatementsNews
Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering
Jupiter, Florida, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a pipeline ...
Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq
Jupiter, Florida, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a pipeline ...
Neuro-inflammation biotech Jupiter Neurosciences revises terms, removes warrants ahead of $15 million IPO
Jupiter Neurosciences, a Phase 1 biotech developing an oral therapy for neuro-inflammation, revised the terms for its upcoming IPO on Tuesday.